Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of apatinib plus etoposide versus apatinib alone in platinum-failed recurrent ovarian cancer
CTR20200826Phase 2Active
- Sponsor
- Hengrui Therapeutics
- Start
- Jul 2020
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 2 trial of Rivoceranib, etoposide in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Hengrui Therapeutics. Started Jul 2020; status: active.
02
Drugs
Rivoceranibetoposide
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on CTR20200826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200826.